Safety and target engagement profile of two oxaloacetate doses in Alzheimer's patients

Volume: 17, Issue: 1, Pages: 7 - 17
Published: Jul 27, 2020
Abstract
Brain bioenergetics are defective in Alzheimer's disease (AD). Preclinical studies find oxaloacetate (OAA) enhances bioenergetics, but human safety and target engagement data are lacking.We orally administered 500 or 1000 mg OAA, twice daily for 1 month, to AD participants (n = 15 each group) and monitored safety and tolerability. To assess brain metabolism engagement, we performed fluorodeoxyglucose positron emission tomography (FDG PET) and...
Paper Details
Title
Safety and target engagement profile of two oxaloacetate doses in Alzheimer's patients
Published Date
Jul 27, 2020
Volume
17
Issue
1
Pages
7 - 17
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.